Join our daily newsletter At The Bell to receive exclusive market insights
- NeuroScientific Biopharmaceuticals (NSB) is on schedule to begin the clinical development of its lead drug candidate, EmtinB, in the first half of 2022
- The company today has submitted an application for an early-phase clinical trial involving EmtinB for Human Research Ethics Committee (HREC) approval
- The timeline for approval is expected to be on par with NSB’s plans to begin its clinical trial in June
- With the HREC review process underway, NeuroScientific says it has officially transitioned from being a preclinical to a clinical-stage company
- NeuroScientific Biopharmaceuticals last traded at 22 cents at 10:32 am AEST
NeuroScientific Biopharmaceuticals (NSB) has reported it is on schedule to begin the clinical development of its lead drug candidate, EmtinB, in the first half of 2022.
The company today said it had submitted an application for an early-phase clinical trial involving EmtinB for Human Research Ethics Committee (HREC) approval.
EmtinB is a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma. The drug has been shown to be safe and well-tolerated at high concentrations and is able to penetrate the blood-brain barrier.
The focus of the planned study will involve the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinB in humans. This can then be used to guide efficacy outcomes during future trials in patients.
The trial will include up to 30 healthy participants and will be undertaken by a leading WA-based clinical research partner, Linear Clinical Research.
The timeline for approval is expected to be on par with NSB’s plans to begin its clinical trial in June.
“Most importantly, the company is one step closer to bringing a much-needed therapeutic option with disease-modifying potential to patients with Alzheimer’s disease and Multiple Sclerosis,” NeuroScientific’s Managing Director and Chief Executive Officer, Matt Liddelow, said.
“With the HREC review process underway and other supporting activities well-advanced, NeuroScientific has officially transitioned from being a preclinical to a clinical-stage company.”
Shares in NeuroScientific Biopharmaceuticals were down 2.27 per cent to 22 cents at 10:32 am AEST
